Get the Stockscreener App
3.74
4.10%
-0.16
Agenus Inc Stock (AGEN) Latest News
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Analysts - Defense World
What is William Blair's Forecast for Agenus FY2024 Earnings? - MarketBeat
Reviewing Innate Pharma (NASDAQ:IPHA) and Agenus (NASDAQ:AGEN) - Defense World
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
FY2024 Earnings Forecast for Agenus Issued By William Blair - Defense World
SaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine Development - Galveston County Daily News
Agenus reports promising sarcoma study results - MSN
Agenus reports publication of data from bot/bal combination in JOCO - TipRanks
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas - Business Wire
AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Agenus continues partnership talks for anti-CTLA-4 combo with new Phase 2 data - Endpoints News
Agenus’ (AGEN) Neutral Rating Reiterated at HC Wainwright - Defense World
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - GlobeNewswire Inc.
Agenus reports promising colorectal cancer treatment data - MSN
Barclays PLC Buys 20,777 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus reports promising colorectal cancer treatment data By Investing.com - Investing.com UK
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease - The Bakersfield Californian
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN) - MarketBeat
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - Morningstar
Guardant Health Inc (GH-Q) QuotePress Release - The Globe and Mail
Cervical Cancer Market Expected to Experience Major Growth - openPR
What Makes Agenus (AGEN) a New Buy Stock - Yahoo Finance
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agenus Inc. (NASDAQ:AGEN) Stock Holdings Lessened by Jane Street Group LLC - Defense World
Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by Analysts - MarketBeat
$960 Mn Vaccine Adjuvants Market by Product, ROA, Disease - GlobeNewswire
$960 Mn Vaccine Adjuvants Market by Product, ROA, Disease Type, VaccineGlobal Forecast to 2029 with GSK, Seppic, Croda, SPI Pharma, Phibro Animal Health, Agenus, Dynavax Technologies Dominating - Yahoo Finance UK
Barclays PLC Purchases 20,777 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
State Street Corp Boosts Position in Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus Inc. (NASDAQ:AGEN) Short Interest Up 6.5% in December - Defense World
HighTower Advisors LLC Boosts Holdings in Agenus Inc. (NASDAQ:AGEN) - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming DeadlinesAGEN - The Eastern Progress Online
AGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Agenus Inc. Invest - GuruFocus.com
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Inve - GuruFocus.com
Agenus (AGEN) Stock Surges Amid Positive Market Movement - GuruFocus.com
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers - Business Wire
Agenus to Present Groundbreaking Colorectal Cancer Treatment Data at ASCO GI Symposium - StockTitan
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
BNP Paribas Financial Markets Acquires 37,866 Shares of Agenus Inc. (NASDAQ:AGEN) - Defense World
Agenus (AGEN) Stock Plummets 5.08% Amidst Mixed Ratings - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Agenus Inc. Class Action: The Gross Law Firm Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024AGEN - Kilgore News Herald
Agenus Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationAGEN - The Eastern Progress Online
Shareholders that lost money on Agenus Inc.(AGEN) Urged to Join Class ActionContact The Gross Law Firm to Learn More - Victoria Advocate
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus - BioSpace
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - The Eastern Progress Online
Shareholders that lost money on Agenus Inc.(AGEN) should contact The Gross Law Firm about pending Class Action - Longview News-Journal
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):